# A Study of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) in Healthy Adult Panelists

> **NCT06299696** · PHASE1 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 10 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** VNZ/TEZ/D-IVA

## Key facts

- **NCT ID:** NCT06299696
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-26
- **Primary completion:** 2024-04-16
- **Final completion:** 2024-04-16
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2024-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06299696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06299696, "A Study of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) in Healthy Adult Panelists". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT06299696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*